Citadel Advisors
KMTS

Citadel Advisors’s Kestra Medical Technologies KMTS Stock Holding History

Citadel Advisors’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$278K Sell
13,943
-29,700
-68% -$700K ﹤0.01% 10648
2025
Q4 		$1.16M Buy
+43,643
New +$1.12M ﹤0.01% 7069
2025
Q3 		– Sell
-1,508,298
Closed -$25M – 14537
2025
Q2 		$25M Buy
1,508,298
+578,168
+62% +$12.6M ﹤0.01% 1892
2025
Q1 		$23.2M Buy
+930,130
New +$21.4M ﹤0.01% 1873

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors's KMTS Position: Q1 2026 in Review

Citadel Advisors reduced its Kestra Medical Technologies (KMTS) stake by 68% in Q1 2026, selling an estimated $700K and leaving 13,943 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #10648.

Citadel Advisors first reported a position in KMTS in Q1 2025 and has held it in 4 quarters since. The position peaked at $25M in Q2 2025. 103 funds tracked by Wall St. Rank hold KMTS as of Q1 2026.

  • Citadel Advisors held 13,943 shares of Kestra Medical Technologies worth $278K as of Q1 2026.
  • Citadel Advisors sold 29,700 Kestra Medical Technologies shares in Q1 2026, an estimated $700K.
  • Kestra Medical Technologies made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10648 holding.
  • Citadel Advisors first reported a position in Kestra Medical Technologies in Q1 2025 and has held it in 4 quarters since.
  • Citadel Advisors's Kestra Medical Technologies position peaked at $25M in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.